FIELD: medicine.
SUBSTANCE: invention refers to biotechnology, namely to a method for searching target proteins triggering the process of cancerogenesis, in individual patient's tissue samples for purposes of the subsequent antitumour therapy. A sequencing method is used to obtain transcriptomic data on gene expression levels in the samples. A kit of activated gene-control networks consisting of a central control gene and controlled genes, is produced. Differential expressed genes are derived from the transcriptomic data. The sequencing methods are used to trace variations in DNA sequences presented in the form of a set of single-nucleotide polymorphisms in the samples. Driver genes are specified among the detected genetic variations. Canonical signal pathways considerably enriched with the pre-detected central expression-control genes, differentially expressed genes, genes with identified single-nucleotide polymorphisms, and indel driver genes are searched. By means of a direct search method, the identified signal pathways are analysed to detect the components - existing proteins targeted by medicinal products for the antitumour therapy.
EFFECT: presented invention enables the high-efficacy detection of the target proteins triggering the process of cancerogenesis, in the individual patient's tissue samples.
1 dwg, 5 tbl
Title | Year | Author | Number |
---|---|---|---|
ANTICANCER INDIVIDUAL PROTEOME-BASED TARGET CELL PREPARATION, METHOD FOR PRODUCING AND USING THIS PREPARATION FOR THERAPY OF CANCER AND OTHER MALIGNANT NEW GROWTHS | 2012 |
|
RU2535972C2 |
ONCOBOX GENETIC INFORMATION ANALYSIS PLATFORM | 2018 |
|
RU2741703C1 |
METHOD OF PRODUCING A PHARMACEUTICAL AGENT FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2719033C2 |
METHOD FOR DEVELOPING BIOMARKERS OF DISEASES AND PHYSIOLOGICALLY ACTIVE SUBSTANCES BASED ON EXTENDED VERSION OF THE IPANDA ALGORITHM | 2018 |
|
RU2703534C1 |
ANTITUMOR TARGET CELL PRODUCT, METHOD FOR ITS PRODUCTION AND ITS APPLICATION | 2018 |
|
RU2757812C2 |
METHOD FOR DETECTION OF PRIMARY REFRACTORY FORM OF MULTIPLE MYELOMA AT THE DISEASE ONSET | 2020 |
|
RU2749612C1 |
INDIVIDUALISED VACCINES FOR CANCER | 2012 |
|
RU2670745C9 |
INDIVIDUALIZED ANTI-TUMOR VACCINES | 2012 |
|
RU2779946C2 |
ANTICANCER COMPOSITION | 2016 |
|
RU2728748C2 |
CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
Authors
Dates
2016-03-10—Published
2013-10-04—Filed